|
|
 |
FD&C BLUE NO. 1 Drug Excipient Business Development Opportunity Report, 2024 |
$399.00 |
|
$399.00 |
|
|
 |
ACTOPLUS MET Drug Profile, 2024 |
$399.00 |
|
$399.00 |
|
|
 |
DEXTROSE Drug Excipient Business Development Opportunity Report, 2024 |
$399.00 |
|
$399.00 |
|
|
 |
ETHYLCELLULOSES Drug Excipient Business Development Opportunity Report, 2024 |
$399.00 |
|
$399.00 |
|
|
 |
DIHYDROXYALUMINUM AMINOACETATE Drug Excipient Business Development Opportunity Report, 2024 |
$399.00 |
|
$399.00 |
|
|
 |
DIMETHYL SULFOXIDE Drug Excipient Business Development Opportunity Report, 2024 |
$399.00 |
|
$399.00 |
|
|
 |
EDETATE CALCIUM DISODIUM Drug Excipient Business Development Opportunity Report, 2024 |
$399.00 |
|
$399.00 |
|
|
 |
ETHYLCELLULOSE Drug Excipient Business Development Opportunity Report, 2024 |
$399.00 |
|
$399.00 |
|
|
 |
DEXTROSE MONOHYDRATE Drug Excipient Business Development Opportunity Report, 2024 |
$399.00 |
|
$399.00 |
|
|
 |
AIRDUO RESPICLICK Drug Profile, 2024 |
$399.00 |
|
$399.00 |
|
|
 |
DOCUSATE SODIUM Drug Excipient Business Development Opportunity Report, 2024 |
$399.00 |
|
$399.00 |
|
|